HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Feasibility and benefit of concurrent chemoradiotherapy for elderly patients with uterine cervical cancer.

AbstractBACKGROUND:
Elderly patients with uterine cervical cancer reportedly have a poorer prognosis than younger patients. Until now, the benefit of concurrent chemoradiotherapy (CCRT) for elderly patients has been considered limited.
METHODS:
We retrospectively analyzed 49 women with cervical cancer aged >70 years primarily treated with radiotherapy (RT) or CCRT in our institute between 2003 and 2014. Treatment compliance, toxicity, and survival benefit were analyzed.
RESULTS:
A total of 49 patients were identified in this retrospective analysis. Twenty patients with a median age of 75.4 years (range 70-77) were treated with CCRT and 29 patients with a median age of 77.9 years (range 70-89) underwent RT. In the CCRT group, 14 patients (70%) completed CCRT consisting of radiotherapy and 5 courses of cisplatin plus 5-fluorouracil including patients requiring a dose reduction of chemotherapy. The median overall survival (OS) in the CCRT and RT groups was 66.9 and 60.1 months, respectively (p = 0.156). The most common grade 3/4 acute toxicity was hyponatremia (35.0%), followed by neutropenia (15.0%) and diarrhea (10.0%) in the CCRT group, while this was anemia (17.2%) followed by radiation enteritis (10.3%) in the RT group.
CONCLUSIONS:
CCRT was well tolerated in elderly patients with cervical cancer. Careful attention should be paid to the different characteristics of treatment-related toxicities in this group compared with younger patients.
AuthorsKazuto Nosaka, Kiyosumi Shibata, Fumi Utsumi, Kosuke Yoshida, Kaoru Niimi, Ryuichiro Sekiya, Shiro Suzuki, Hiroaki Kajiyama, Fumitaka Kikkawa
JournalTumori (Tumori) Vol. 102 Issue 6 Pg. 600-605 (Dec 01 2016) ISSN: 2038-2529 [Electronic] United States
PMID27443893 (Publication Type: Journal Article)
Topics
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Chemoradiotherapy (adverse effects, methods)
  • Comorbidity
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Neoplasm Staging
  • Patient Compliance
  • Retrospective Studies
  • Treatment Outcome
  • Uterine Cervical Neoplasms (diagnosis, mortality, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: